AffyImmune Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- AffyImmune Therapeutics's estimated annual revenue is currently $2.8M per year.
- AffyImmune Therapeutics's estimated revenue per employee is $155,000
- AffyImmune Therapeutics's total funding is $28.9M.
- AffyImmune Therapeutics has 18 Employees.
- AffyImmune Therapeutics grew their employee count by 50% last year.
AffyImmune Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is AffyImmune Therapeutics?
Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.keywords:N/A
Number of Employees
Employee Growth %
AffyImmune Therapeutics News
NATICK, Mass., April 6, 2022 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company using its Tune & Track...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|